Episode notes
Dyslipidemia is a well-known risk factor for the development of cardiovascular disease, a leading cause of morbidity and mortality. Treatment of dyslipidemia represents one of the most crucial strategies to reduce risk of atherosclerotic cardiovascular (CV) disease (ASCVD). In this podcast series, Dr. Deepak Bhatt and Dr. R. Scott Wright discuss recent clinical trial evidence for CV risk reduction with cholesterol-lowering therapies, with a focus on CV outcomes trials with current and emerging therapies that target proprotein convertase subtilisin/kexin type 9 (PCSK9).Launch Date: February 16, 2024Release Date: January 29, 2024Expiration Date: January 31, 2025
FACULTY
R. Scott Wright, MD, FACC, FESC, FAHA
Professor of Medicine
Consultant in Cardiology
Mayo Clinic
Deepak L. Bhatt, ...